Skip to main content

Research Repository

Advanced Search

Alliance between selective serotonin reuptake inhibitors and fracture risk: an updated systematic review and meta-analysis

Kumar, Manoj; Bajpai, Ram; Shaik, Abdul Rahaman; Vohora, Divya; Srivastava, Swati

Alliance between selective serotonin reuptake inhibitors and fracture risk: an updated systematic review and meta-analysis Thumbnail


Authors

Manoj Kumar

Abdul Rahaman Shaik

Divya Vohora

Swati Srivastava



Abstract

Purpose In the past few years, several fracture-related events have been reported with chronic use of selective serotonin reuptake inhibitors (SSRIs) throughout the globe. Hence, an updated systematic review and meta-analysis was necessary to ascertain the risk involved. The present work evaluated the association of SSRIs with the risk of fracture in adults. Methods We systematically searched PubMed, Cochrane library, and Google Scholar for observational studies on the same from inception to April 2019. Screening, data extraction, and risk of bias assessment were conducted independently by 2 authors. Results We assessed 69 studies out of which 37 (14 case-control, 23 cohorts) were included. Our results showed that SSRIs were significantly associated with an increased fracture risk (relative risk of 1.62, 95% CI 1.52–1.73; P?<?0.000; I2 = 90.8%). The relative risk values for case-control and cohort studies were found to be 1.80 (95% CI 1.58–2.03; P?<?0.000; I2 = 93.2%) and 1.51 (95% CI 1.39–1.64; P?<?0.000; I2 = 88.0%) respectively. Subgroup analysis showed that association of risk of fracture persisted regardless of geographical location, study design, risk factors, defined daily dose, SSRI use duration, site of the fracture, period of study and after adjusting for depression, physical activity, gender, and age group. The sensitivity analysis data shows that the studies adjusted for bone mineral density and osteoporosis show lesser fracture risk. Conclusion Our findings suggests that SSRIs may be associated with an increased fracture risk; hence, bone health should be taken into consideration while prescribing this class of drugs.

Journal Article Type Article
Acceptance Date May 8, 2020
Online Publication Date Jun 16, 2020
Publication Date 2020-10
Publicly Available Date Mar 29, 2024
Journal European Journal of Clinical Pharmacology
Print ISSN 0031-6970
Publisher Springer Verlag
Peer Reviewed Peer Reviewed
Volume 76
Issue 10
Pages 1373–1392
DOI https://doi.org/10.1007/s00228-020-02893-1
Publisher URL https://link.springer.com/article/10.1007%2Fs00228-020-02893-1#article-info